Physician profile
Manish V Sheth
NPI 1225083272
$9,895.17
in general payments reported to CMS, 2019-2025
31 companies · $1,833 in 2025
The $1,833 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,521 · 2020: $977 · 2021: $1,529 · 2022: $1,617 · 2023: $1,415 · 2024: $1,004 · 2025: $1,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,251.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,783.92 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $905.54 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $861.39 | 2019-2025 | Rexulti |
| Abbvie INC. | $798.22 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $684.59 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $630.22 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $622.60 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $485.64 | 2019-2022 | |
| Axsome Therapeutics, INC. | $425.79 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $312.61 | 2021-2022 | |
| Allergan, INC. | $253.22 | 2019-2020 | |
| Indivior INC. | $241.53 | 2019-2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $204.13 | 2019-2023 | Austedo Xr |
| Alkermes, INC. | $191.28 | 2020-2025 | Aristada, Lybalvi |
| Tempus Ai, INC | $178.28 | 2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $176.53 | 2019-2025 | Deep Tms System |
| Corium, LLC | $170.35 | 2023-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $138.00 | 2025 | Cobenfy |
| Csl Behring | $124.77 | 2022 | |
| Supernus Pharmaceuticals, INC. | $106.23 | 2021-2023 | Qelbree |
| Sage Therapeutics, LLC | $106.13 | 2020 | |
| Neos Therapeutics, LP | $97.90 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $90.37 | 2025 | Spravato |
| Merck Sharp & Dohme LLC | $66.69 | 2022 | |
| Shire North American Group INC | $60.09 | 2019 | |
| Livanova USA, INC. | $45.27 | 2022-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Alfasigma USA, INC. | $43.42 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $37.42 | 2020-2023 | Jornay Pm |
| Boston Scientific Corporation | $19.50 | 2023 | Infinion 16 |
| Lilly USA, LLC | $18.55 | 2020 | |
| Bausch Health US, LLC | $14.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.